Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22988089 | 0.83 | HSP90AB1 (0.41) | ADORA2AROCK2ROCK1 | |
| SCHEMBL22987708 | 0.83 | NR1H2 (0.48) | ADORA3XDHNR1H2NR1H3ADORA2A | |
| SCHEMBL22987510 | 0.82 | NR1H2 (0.50) | ADORA3XDHNR1H2NR1H3ADORA2A | |
| SCHEMBL22987660 | 0.81 | POLB (0.48) | ADORA3XDHADORA2A | |
| SCHEMBL29646424 | 0.80 | ADORA3 (0.38) | P2RX7ADORA3NR1H2NR1H3ADORA2A | |
| SCHEMBL22978982 | 0.80 | ADORA3 (0.38) | P2RX7ADORA3NR1H2NR1H3ADORA2A | |
| SCHEMBL22979629 | 0.80 | PIK3CD (0.37) | ADORA3XDHADORA2A | |
| SCHEMBL22988248 | 0.80 | HSP90AA1 (0.35) | ADORA3NR1H2NR1H3ADORA2A | |
| SCHEMBL22987630 | 0.80 | PDK2 (0.36) | ADORA3NR1H2NR1H3ADORA2A | |
| SCHEMBL22987505 | 0.80 | NR1H2 (0.41) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | EGFR 1152/4885P2RX7 76/4885ADORA3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.